Martingale Asset Management L P Has $833,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Martingale Asset Management L P decreased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 26.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,087 shares of the specialty pharmaceutical company's stock after selling 10,700 shares during the period. Martingale Asset Management L P owned 0.09% of Collegium Pharmaceutical worth $833,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC grew its stake in Collegium Pharmaceutical by 1,532.2% in the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company's stock valued at $1,459,000 after purchasing an additional 35,439 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Collegium Pharmaceutical by 17.2% in the 3rd quarter. Wellington Management Group LLP now owns 114,640 shares of the specialty pharmaceutical company's stock valued at $4,430,000 after buying an additional 16,784 shares during the last quarter. Barclays PLC boosted its holdings in shares of Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after buying an additional 45,291 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Collegium Pharmaceutical by 0.7% in the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock valued at $29,974,000 after buying an additional 5,464 shares in the last quarter. Finally, TD Private Client Wealth LLC increased its holdings in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after buying an additional 483 shares during the last quarter.

Remove Ads

Analysts Set New Price Targets

A number of analysts have commented on COLL shares. StockNews.com upgraded shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday. Piper Sandler reduced their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Buy" and an average price target of $43.60.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock traded up $0.39 during trading hours on Tuesday, hitting $27.12. The company had a trading volume of 358,999 shares, compared to its average volume of 443,989. The firm has a market cap of $871.42 million, a PE ratio of 11.69 and a beta of 0.76. The firm has a 50-day moving average of $28.98 and a 200 day moving average of $31.44. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million for the quarter, compared to analysts' expectations of $179.68 million. On average, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now owns 124,421 shares in the company, valued at approximately $3,732,630. This trade represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock worth $2,334,994 in the last quarter. Corporate insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.